logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Trick or Trade

Serious is the Impact of Bad Circumstances

The Impact of Bad Circumstances Since early year 2024, in every Prohost Letter we have posted, we added a memo stating that we have decided to be careful not to underestimate the bad circumstances under which the world is currently...

Read More

August 6, 2024

0

Kite Pharma’s Yescarta® Approved by the EC for Adults with Relapsed or Refractory Follicular Lymphoma

Kite Pharma - A Gilead Company In The NEWS Gilead Sciences' ( GILD ) firm Kite Pharma, announced that the European Commission ( EC ) has approved its CAR T-cell therapy Yescarta® (axicabtagene ciloleucel) for adult patients with relapsed or refractory...

Read More

June 29, 2022

0

Acquired by Merck or Not, Seagen Will, Sooner or Later, Outperform

Is Merck to Acquire Seagen? The Wall Street Journal reported that Merck is in advanced talks to buy Seagen in a deal that could be worth $40 billion or more. The report, cited by people familiar with the matter, said...

Read More

July 8, 2022

0

Merck Discontinues Two Late-Stage Keytruda Trials and Other Important Information

Merck Updates Merck ( MRK ) provided updates on two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630, stating that it discontinued Phase 3 KEYNOTE-867 trial evaluating KEYTRUDA in combination with stereotactic body radiotherapy ( SBRT ) for the treatment of patients...

Read More

August 29, 2024

0

Why Rhythm Pharmaceuticals Stock Price is Rebounding

Rhythm Pharmaceuticals is Rebounding Rhythm Pharmaceuticals ( RYTM ) announced yesterday, July 20, 2022, that the French National Agency for Medicines and Health Products Safety ( ANSM ) and Haute Autorité de santé ( HAS ) have granted pre-marketing authorization...

Read More

July 21, 2022

0

Serious is the Impact of Bad Circumstances

The Impact of Bad Circumstances Since early year 2024, in every Prohost Letter we have posted, we added a memo stating that we have decided to be careful not to underestimate the bad circumstances under which the world is currently...

Read More

August 6, 2024

0

Rhythm Pharmaceuticals & Akero Therapeutics: On the Morning of September 15, 2022

Rhythm Pharmaceuticals Rhythm Pharmaceuticals ( RYTM) : After soaring, based on great scientific and drug performance in treating genetic obesity, the selloff of the stock has occurred today after the firm’s announcement and pricing of its public offering of 4.8M...

Read More

September 15, 2022

0

Merck Discontinues Two Late-Stage Keytruda Trials and Other Important Information

Merck Updates Merck ( MRK ) provided updates on two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630, stating that it discontinued Phase 3 KEYNOTE-867 trial evaluating KEYTRUDA in combination with stereotactic body radiotherapy ( SBRT ) for the treatment of patients...

Read More

August 29, 2024

0

Searching for Biotech Firms with Novel Drugs That Reached Clinical-Stage or Were Granted Early Fast Track Designation

Searching for Biotech Firms The search is for firms biotech firms that have reached clinical stage with novel products that had some earlier, encouraging test results, whose technologies and lead products must have demonstrated  improvement over current treatments of devastating...

Read More

October 28, 2022

0

What We Learned This Morning

Dear Subscribers, This is what we learned this morning: FTX: we learned about the arrest of Sam Bankman Fried and about the firm’s hearing today. We heard from several sources that FTX has been a house of cards built on...

Read More

December 13, 2022

0

  • Previous
  • 1
  • 2
  • ...
  • 14
  • 15
  • 16
  • 17
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy